Breast Cancer: Coordinated Regulation of CCL2 Secretion by Intracellular Glycosaminoglycans and Chemokine Motifs

Neoplasia (United States)

Volumn 16, Issue 9, 2014, Pages 723-740

  Lebel Haziv, Yaeli ^a   Meshel, Tsipi ^a   Soria, Gali ^a   Yeheskel, Adva ^a   Mamon, Elad ^a   Ben Baruch, Adit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84928209378     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2014.08.004     Document Type: Article

References (74)

1. Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009, 30:1073-1081.
2. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
3. Hanahan D., Coussens L.M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 21:309-322.
4. Balkwill F.R., Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol 2012, 22:33-40.
5. Borsig L., Wolf M.J., Roblek M., Lorentzen A., Heikenwalder M. Inflammatory chemokines and metastasis-tracing the accessory. Oncogene 2013, 33:3217-3224.
6. Conti I., Rollins B.J. CCL2 (monocyte chemoattractant protein-1) and cancer. Semin Cancer Biol 2004, 14:149-154.
7. Leibovich-Rivkin T. L-HY, Lerrer S., Weitzenfeld P., Ben-Baruch A. (2013). The versatile world of inflammatory chemokines in cancer. Editor . Springer: City, pp. 135-176.
8. Eferl R. CCL2 at the crossroad of cancer metastasis. JAKSTAT 2013, 2:e23816.
9. Yadav A., Saini V., Arora S. MCP-1: chemoattractant with a role beyond immunity: a review. Clin Chim Acta 2010, 411:1570-1579.
10. Huang B., Lei Z., Zhao J., Gong W., Liu J., Chen Z., Liu Y., Li D., Yuan Y., Zhang G.M., et al. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett 2007, 252:86-92.
11. Soria G., Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 2008, 267:271-285.
12. Verma R., Bowen R.L., Slater S.E., Mihaimeed F., Jones J.L. Pathological and epidemiological factors associated with advanced stage at diagnosis of breast cancer. Br Med Bull 2012, 103:129-145.
13. Ben-Baruch A. The Inflammatory CC Chemokines CCL2 and CCL5 in Malignancy: Leukocyte Migration and Beyond 2012, 99-114. Bentham Science Publishers, Emirate of Sharjah. A. Ben-Baruch (Ed.).
14. Craig M.J., Loberg R.D. CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases. Cancer Metastasis Rev 2006, 25:611-619.
15. Soria G., Ofri-Shahak M., Haas I., Yaal-Hahoshen N., Leider-Trejo L., Leibovich-Rivkin T., Weitzenfeld P., Meshel T., Shabtai E., Gutman M., et al. Inflammatory mediators in breast cancer: Coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer 2011, 11:130-149.
16. Chavey C., Bibeau F., Gourgou-Bourgade S., Burlinchon S., Boissiere F., Laune D., Roques S., Lazennec G. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res 2007, 9:R15.
17. Soria G., Yaal-Hahoshen N., Azenshtein E., Shina S., Leider-Trejo L., Ryvo L., Cohen-Hillel E., Shtabsky A., Ehrlich M., Meshel T., et al. Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactions. Cytokine 2008, 44:191-200.
18. Goede V., Brogelli L., Ziche M., Augustin H.G. Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1. Int J Cancer 1999, 82:765-770.
19. Neumark E., Sagi-Assif O., Shalmon B., Ben-Baruch A., Witz I.P. Progression of mouse mammary tumors: MCP-1-TNFα cross-regulatory pathway and clonal expression of promalignancy and antimalignancy factors. Int J Cancer 2003, 106:879-886.
20. Low-Marchelli J.M., Ardi V.C., Vizcarra E.A., van Rooijen N., Quigley J.P., Yang J. Twist1 induces CCL2 and recruits macrophages to promote angiogenesis. Cancer Res 2013, 73:662-671.
21. Ueno T., Toi M., Saji H., Muta M., Bando H., Kuroi K., Koike M., Inadera H., Matsushima K. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 2000, 6:3282-3289.
22. Lu X., Kang Y. Chemokine (C-C motif) ligand 2 engages CCR2+ stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone. J Biol Chem 2009, 284:29087-29096.
23. Qian B.Z., Li J., Zhang H., Kitamura T., Zhang J., Campion L.R., Kaiser E.A., Snyder L.A., Pollard J.W. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011, 475:222-225.
24. Nakasone E.S., Askautrud H.A., Kees T., Park J.H., Plaks V., Ewald A.J., Fein M., Rasch M.G., Tan Y.X., Qiu J., et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 2012, 21:488-503.
25. Arendt L.M., McCready J., Keller P.J., Baker D.D., Naber S.P., Seewaldt V., Kuperwasser C. Obesity promotes breast cancer by CCL2-mediated macrophage recruitment and angiogenesis. Cancer Res 2013, 73:6080-6093.
26. Zhang Y., Yang P., Sun T., Li D., Xu X., Rui Y., Li C., Chong M., Ibrahim T., Mercatali L., et al. miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat Cell Biol 2013, 15:284-294.
27. Kinder M., Chislock E., Bussard K.M., Shuman L., Mastro A.M. Metastatic breast cancer induces an osteoblast inflammatory response. Exp Cell Res 2008, 314:173-183.
28. Bussard K.M., Okita N., Sharkey N., Neuberger T., Webb A., Mastro A.M. Localization of osteoblast inflammatory cytokines MCP-1 and VEGF to the matrix of the trabecula of the femur, a target area for metastatic breast cancer cell colonization. Clin Exp Metastasis 2010, 27:331-340.
29. Yoshimura T., Howard O.M., Ito T., Kuwabara M., Matsukawa A., Chen K., Liu Y., Liu M., Oppenheim J.J., Wang J.M. Monocyte chemoattractant protein-1/CCL2 produced by stromal cells promotes lung metastasis of 4T1 murine breast cancer cells. PLoS One 2013, 8:e58791.
30. Allavena P., Sica A., Solinas G., Porta C., Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 2008, 66:1-9.
31. Murdoch C., Muthana M., Coffelt S.B., Lewis C.E. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008, 8:618-631.
32. Hembruff S.L., Jokar I., Yang L., Cheng N. Loss of transforming growth factor-β signaling in mammary fibroblasts enhances CCL2 secretion to promote mammary tumor progression through macrophage-dependent and -independent mechanisms. Neoplasia 2010, 12:425-433.
33. Keeley E.C., Mehrad B., Strieter R.M. Chemokines as mediators of neovascularization. Arterioscler Thromb Vasc Biol 2008, 28:1928-1936.
34. Wang S., Xu M., Li F., Wang X., Bower K.A., Frank J.A., Lu Y., Chen G., Zhang Z., Ke Z., et al. Ethanol promotes mammary tumor growth and angiogenesis: the involvement of chemoattractant factor MCP-1. Breast Cancer Res Treat 2012, 133:1037-1048.
35. Niu J., Azfer A., Zhelyabovska O., Fatma S., Kolattukudy P.E. Monocyte chemotactic protein (MCP)-1 promotes angiogenesis via a novel transcription factor, MCP-1-induced protein (MCPIP). J Biol Chem 2008, 283:14542-14551.
36. Weber K.S., Nelson P.J., Gröne H.J., Weber C. Expression of CCR2 by endothelial cells: implications for MCP-1 mediated wound injury repair and in vivo inflammatory activation of endothelium. Arterioscler Thromb Vasc Biol 1999, 19:2085-2093.
37. Salcedo R., Ponce M.L., Young H.A., Wasserman K., Ward J.M., Kleinman H.K., Oppenheim J.J., Murphy W.J. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000, 96:34-40.
38. Garcia-Roman J., Zentella-Dehesa A. Vascular permeability changes involved in tumor metastasis. Cancer Lett 2013, 335:259-269.
39. Wilson T.J., Nannuru K.C., Futakuchi M., Singh R.K. Cathepsin G-mediated enhanced TGF-β signaling promotes angiogenesis via upregulation of VEGF and MCP-1. Cancer Lett 2010, 288:162-169.
40. Nam J.S., Kang M.J., Suchar A.M., Shimamura T., Kohn E.A., Michalowska A.M., Jordan V.C., Hirohashi S., Wakefield L.M. Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells. Cancer Res 2006, 66:7176-7184.
41. Mestdagt M., Polette M., Buttice G., Noel A., Ueda A., Foidart J.M., Gilles C. Transactivation of MCP-1/CCL2 by β-catenin/TCF-4 in human breast cancer cells. Int J Cancer 2006, 118:35-42.
42. Prest S.J., Rees R.C., Murdoch C., Marshall J.F., Cooper P.A., Bibby M., Li G., Ali S.A. Chemokines induce the cellular migration of MCF-7 human breast carcinoma cells: subpopulations of tumour cells display positive and negative chemotaxis and differential in vivo growth potentials. Clin Exp Metastasis 1999, 17:389-396.
43. Robinson S.C., Scott K.A., Balkwill F.R. Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-α. Eur J Immunol 2002, 32:404-412.
44. Soria G., Lebel-Haziv Y., Ehrlich M., Meshel T., Suez A., Avezov E., Rozenberg P., Ben-Baruch A. Mechanisms regulating the secretion of the promalignancy chemokine CCL5 by breast tumor cells: CCL5's 40s loop and intracellular glycosaminoglycans. Neoplasia 2012, 14:1-19.
45. Proudfoot A.E., Fritchley S., Borlat F., Shaw J.P., Vilbois F., Zwahlen C., Trkola A., Marchant D., Clapham P.R., Wells T.N. The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity. J Biol Chem 2001, 276:10620-10626.
46. Martin L., Blanpain C., Garnier P., Wittamer V., Parmentier M., Vita C. Structural and functional analysis of the RANTES-glycosaminoglycans interactions. Biochemistry 2001, 40:6303-6318.
47. Proudfoot A.E. The biological relevance of chemokine-proteoglycan interactions. Biochem Soc Trans 2006, 34:422-426.
48. Salanga C.L., Handel T.M. Chemokine oligomerization and interactions with receptors and glycosaminoglycans: the role of structural dynamics in function. Exp Cell Res 2011, 317:590-601.
49. Hol J., Küchler A.M., Johansen F.E., Dalhus B., Haraldsen G., Oynebråten I. Molecular requirements for sorting of the chemokine interleukin-8/CXCL8 to endothelial Weibel-Palade bodies. J Biol Chem 2009, 284:23532-23539.
50. El Golli N., Issertial O., Rosa J.P., Briquet-Laugier V. Evidence for a granule targeting sequence within platelet factor 4. J Biol Chem 2005, 280:30329-30335.
51. Lau E.K., Paavola C.D., Johnson Z., Gaudry J.P., Geretti E., Borlat F., Kungl A.J., Proudfoot A.E., Handel T.M. Identification of the glycosaminoglycan binding site of the CC chemokine, MCP-1: implications for structure and function in vivo. J Biol Chem 2004, 279:22294-22305.
52. Chakravarty L., Rogers L., Quach T., Breckenridge S., Kolattukudy P.E. Lysine 58 and histidine 66 at the C-terminal α-helix of monocyte chemoattractant protein-1 are essential for glycosaminoglycan binding. J Biol Chem 1998, 273:29641-29647.
53. Voss M.J., Möller M.F., Powe D.G., Niggemann B., Zänker K.S., Entschladen F. Luminal and basal-like breast cancer cells show increased migration induced by hypoxia, mediated by an autocrine mechanism. BMC Cancer 2011, 11:158.
54. Rohl C.A., Strauss C.E., Misura K.M., Baker D. Protein structure prediction using Rosetta. Methods Enzymol 2004, 383:66-93.
55. Davis I.W., Leaver-Fay A., Chen V.B., Block J.N., Kapral G.J., Wang X., Murray L.W., Arendall W.B., Snoeyink J., Richardson J.S., et al. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res 2007, 35:W375-W383.
56. Lubkowski J., Bujacz G., Boqué L., Domaille P.J., Handel T.M., Wlodawer A. The structure of MCP-1 in two crystal forms provides a rare example of variable quaternary interactions. Nat Struct Biol 1997, 4:64-69.
57. Gowda D.C., Bhavanandan V.P., Davidson E.A. Isolation and characterization of proteoglycans secreted by normal and malignant human mammary epithelial cells. J Biol Chem 1986, 261:4926-4934.
58. Gowda D.C., Bhavanandan V.P., Davidson E.A. Isolation and characterization of membrane-associated proteoglycans from normal and malignant human mammary epithelial cells. Glycoconjugate J 1986, 3:55-70.
59. Johnson Z., Proudfoot A.E., Handel T.M. Interaction of chemokines and glycosaminoglycans: a new twist in the regulation of chemokine function with opportunities for therapeutic intervention. Cytokine Growth Factor Rev 2005, 16:625-636.
60. Esko J.D., Stewart T.E., Taylor W.H. Animal cell mutants defective in glycosaminoglycan biosynthesis. Proc Natl Acad Sci U S A 1985, 82:3197-3201.
61. Gotting C., Kuhn J., Kleesiek K. Human xylosyltransferases in health and disease. Cell Mol Life Sci 2007, 64:1498-1517.
62. Gingis-Velitski S., Zetser A., Kaplan V., Ben-Zaken O., Cohen E., Levy-Adam F., Bashenko Y., Flugelman M.Y., Vlodavsky I., Ilan N. Heparanase uptake is mediated by cell membrane heparan sulfate proteoglycans. J Biol Chem 2004, 279:44084-44092.
63. Multhaupt H.A., Couchman J.R. Heparan sulfate biosynthesis: methods for investigation of the heparanosome. J Histochem Cytochem 2013, 60:908-915.
64. Nadanaka S., Kitagawa H. Heparan sulphate biosynthesis and disease. J Biochem 2008, 144:7-14.
65. Sarrazin S., Lamanna W.C., Esko J.D. Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol 2011, 3.
66. Hemmerich S., Paavola C., Bloom A., Bhakta S., Freedman R., Grunberger D., Krstenansky J., Lee S., McCarley D., Mulkins M., et al. Identification of residues in the monocyte chemotactic protein-1 that contact the MCP-1 receptor, CCR2. Biochemistry 1999, 38:13013-13025.
67. Jiang Y., Valente A.J., Williamson M.J., Zhang L., Graves D.T. Post-translational modification of a monocyte-specific chemoattractant synthesized by glioma, osteosarcoma, and vascular smooth muscle cells. J Biol Chem 1990, 265:18318-18321.
68. Ruggiero P., Flati S., Di Cioccio V., Maurizi G., Macchia G., Facchin A., Anacardio R., Maras A., Lucarelli M., Boraschi D. Glycosylation enhances functional stability of the chemotactic cytokine CCL2. Eur Cytokine Netw 2003, 14:91-96.
69. Ishii K., Yamagami S., Tanaka H., Motoki M., Suwa Y., Endo N. Full active baculovirus-expressed human monocyte chemoattractant protein 1 with the intact N-terminus. Biochem Biophys Res Commun 1995, 206:955-961.
70. Kolset S.O., Prydz K., Pejler G. Intracellular proteoglycans. Biochem J 2004, 379:217-227.
71. Zehe C., Engling A., Wegehingel S., Schäfer T., Nickel W. Cell-surface heparan sulfate proteoglycans are essential components of the unconventional export machinery of FGF-2. Proc Natl Acad Sci U S A 2006, 103:15479-15484.
72. Takahashi I., Noguchi N., Nata K., Yamada S., Kaneiwa T., Mizumoto S., Ikeda T., Sugihara K., Asano M., Yoshikawa T., et al. Important role of heparan sulfate in postnatal islet growth and insulin secretion. Biochem Biophys Res Commun 2009, 383:113-118.
73. Wagner L., Yang O.O., Garcia-Zepeda E.A., Ge Y., Kalams S.A., Walker B.D., Pasternack M.S., Luster A.D. Beta-chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans. Nature 1998, 391:908-911.
74. Meen A.J., Øynebråten I., Reine T.M., Duelli A., Svennevig K., Pejler G., Jenssen T., Kolset S.O. Serglycin is a major proteoglycan in polarized human endothelial cells and is implicated in the secretion of the chemokine GROalpha/CXCL1. J Biol Chem 2011, 286:2636-2647.